Product Pipeline

Our innovative approach to drug development has resulted in a pipeline of drug candidates that offer novel, differentiated treatments for a range of chronic diseases, including autoimmune and central nervous system (CNS) diseases.

Lead Indications
Preclinical
Phase 1
Phase 2
Phase 3
plus-minus
CTP-543 Deuterated ruxolitinib
Alopecia Areata
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

An investigational JAK inhibitor designed to target the immunological basis of alopecia areata. CTP-543 is an oral inhibitor of Janus kinases JAK1 and JAK2. Learn more >

plus-minus
CTP-692 Deuterated D-serine
Schizophrenia
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 
Additional CNS Indications
Preclinical
Phase 1
Phase 2
Phase 3
 
 
 
 

An investigational deuterium-modified form of D-serine for the adjunctive treatment of schizophrenia. CTP-692 is being investigated as a treatment for positive and negative symptoms as well as cognitive dysfunction to more broadly treat the symptoms of schizophrenia than has been previously possible. Learn more >


Warning: Illegal string offset 'avp_786_text' in /home/concertp/public_html/wp-content/themes/Orchestra/page-pipeline.php on line 203

Strategic Collaborations

Concert’s platform has driven product development programs and resulted in novel drugs that are being developed under strategic collaborations.

Back to Top